Skip to content

Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers

Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05304494
Enrollment
0
Registered
2022-03-31
Start date
2022-03-31
Completion date
2024-03-31
Last updated
2022-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Asthma Chronic, Breathlessness, COPD, Dyspnea, Shortness of Breath, Wheezing

Keywords

Breathlessness, COPD, Asthma, Asthma Chronic, Wheezing, Dyspnea, Shortness of Breath

Brief summary

The Sentinel-001 study aims to identify a combination of biomarkers suitable for triage of breathlessness.

Interventions

OTHERBiomarker tests for participant profiling

Combination of digital and physical tests to objectify measures relevant for breathlessness

Sponsors

Sanome
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18-90 years. * Has experienced episode of breathlessness during the past 12 months triggering interaction with a health care professional. Self-reported breathlessness using any of the following words to describe symptoms will qualify as a presentation of breathlessness regardless of aetiology or severity of symptoms: shortness of breath, tight chest, trouble breathing, breathlessness, dyspnoeic, breathless, asthmatic, suffocating, wheezing, fighting for breath or any equivalent word. Breathlessness does not have to be the primary presenting symptom. * Deemed clinically sufficiently stable to participate according to health care practitioner.

Exclusion criteria

* Inability to understand written local language at a year 5 level. * Not being confident in use of digital technology (smartphone and/or tablet). This will become evident through an inability to use the system. * Inability to enter required study sample data due to diminished consciousness and/or physical or mental capacity regardless of whether this is associated with the breathlessness event. * Received an investigational medical product in the context of a Clinical Trial during the 28 days prior to first probe administration.

Design outcomes

Primary

MeasureTime frameDescription
Physician assessed severity of breathlessness1 day (One-time assessment during a participant reported episode of breathlessness)Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \< 24 hours, Breathlessness requiring medical intervention within 24 hours without meeting the criteria for severe breathlessness, Breathlessness not requiring any medical intervention within 24 hours other than a dose change in the individuals pre-established pharmacological treatment plan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026